The Role of Electronic Noses in Phenotyping Patients with Chronic Obstructive Pulmonary Disease

被引：2
作者：
Scarlata S. [1 ]
Finamore P. [2 ]
Meszaros M. [3 ]
Dragonieri S. [4 ]
Bikov A. [5 ,6 ]
机构：
[1] Unit of Internal Medicine, Campus Bio Medico University and Teaching Hospital, Rome
[2] Unit of Geriatrics, Campus Bio Medico University and Teaching Hospital, Rome
[3] Department of Pulmonology and Sleep Disorders Centre, University Hospital Zürich, Zurich
[4] Respiratory and Sleep Medicine Unit, Policlinico University Hospital, University of Bari Aldo Moro, Bari
[5] Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester
[6] Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester
来源：
Biosensors | 2020年 / 10卷 / 11期
关键词：
chronic obstructive pulmonary disease; COPD; e-nose; electronic nose; VOCs; volatile organic compounds;
D O I：
10.3390/BIOS10110171
中图分类号：
学科分类号：
摘要：
Chronic obstructive pulmonary disease (COPD) is a common progressive disorder of the respiratory system which is currently the third leading cause of death worldwide. Exhaled breath analysis is a non-invasive method to study lung diseases, and electronic noses have been extensively used in breath research. Studies with electronic noses have proved that the pattern of exhaled volatile organic compounds is different in COPD. More recent investigations have reported that electronic noses could potentially distinguish different endotypes (i.e., neutrophilic vs. eosinophilic) and are able to detect microorganisms in the airways responsible for exacerbations. This article will review the published literature on electronic noses and COPD and help in identifying methodological, physiological, and disease-related factors which could affect the results. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
引用
收藏
相关论文
共 124 条
  • [1] Vogelmeier C.F., Criner G.J., Martinez F.J., Anzueto A., Barnes P.J., Bourbeau J., Celli B.R., Chen R., Decramer M., Fabbri L.M., Et al., Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary, Eur. Respir. J., 49, (2017)
  • [2] Barnes P.J., Burney P.G., Silverman E.K., Celli B.R., Vestbo J., Wedzicha J.A., Wouters E.F., Chronic obstructive pulmonary disease, Nat. Rev. Dis. Primers, 1, (2015)
  • [3] Lange P., Celli B., Agusti A., Boje Jensen G., Divo M., Faner R., Guerra S., Marott J.L., Martinez F.D., Martinez-Camblor P., Et al., Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease, N. Engl. J. Med., 373, pp. 111-122, (2015)
  • [4] Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Et al., Susceptibility to exacerbation in chronic obstructive pulmonary disease, N. Engl. J. Med., 363, pp. 1128-1138, (2010)
  • [5] Pascoe S., Locantore N., Dransfield M.T., Barnes N.C., Pavord I.D., Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials, Lancet. Respir. Med., 3, pp. 435-442, (2015)
  • [6] Calverley P.M.A., Tetzlaff K., Vogelmeier C., Fabbri L.M., Magnussen H., Wouters E.F.M., Mezzanotte W., Disse B., Finnigan H., Asijee G., Et al., Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease, Am. J. Respir. Crit. Care Med., 196, pp. 1219-1221, (2017)
  • [7] Bafadhel M., Haldar K., Barker B., Patel H., Mistry V., Barer M.R., Pavord I.D., Brightling C.E., Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: Relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function, Int. J. Chronic Obstr. Pulm. Dis., 10, pp. 1075-1083, (2015)
  • [8] Bafadhel M., McKenna S., Terry S., Mistry V., Pancholi M., Venge P., Lomas D.A., Barer M.R., Johnston S.L., Pavord I.D., Et al., Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial, Am. J. Respir. Crit. Care Med., 186, pp. 48-55, (2012)
  • [9] Di Pasquale M., Aliberti S., Mantero M., Gramegna A., Blasi F., Pharmacotherapeutic management of bronchial infections in adults: Non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease, Expert Opin. Pharmacother., pp. 1-15, (2020)
  • [10] Horvath I., Barnes P.J., Loukides S., Sterk P.J., Hogman M., Olin A.C., Amann A., Antus B., Baraldi E., Bikov A., Et al., A European Respiratory Society technical standard: Exhaled biomarkers in lung disease, Eur. Respir. J., 49, (2017)
12345678910